Current Report Filing (8-k)
November 08 2021 - 04:16PM
Edgar (US Regulatory)
0001417926
false
0001417926
2021-11-02
2021-11-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 2, 2021
INVO
BIOSCIENCE, INC.
(Exact
name of registrant as specified in charter)
Nevada
|
|
001-39701
|
|
20-4036208
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
5582
Broadcast Court
Sarasota,
Florida
|
|
34240
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (978) 878-9505
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.0001 par value per share
|
|
INVO
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2
of this chapter)
Emerging
growth company ☐.
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.02 Termination of a Material Definitive Agreement.
On
November 2, 2021, Ferring International Center S.A. (“Ferring”), notified us of its intention to terminate that certain Distribution
Agreement dated November 12, 2018 by and among Ferring, INVO Bioscience, Inc. (“INVO”), and Bio X Cell, Inc., (the “Agreement”).
Ferring gave notice of termination for convenience under Section 14.2(b) of the Agreement which requires 90-days prior written notice.
Accordingly, the Agreement will officially terminate on January 31, 2022. Capitalized terms used and not otherwise defined have the meanings
set forth in the Agreement.
Pursuant
to the terms of the Agreement, for ninety (90) days after the expiration or termination, Ferring shall use Commercially Reasonable Efforts
to transition any customers for the Product in the Territory to INVO and otherwise facilitate the orderly transition of the distribution
of the Product in the Territory from Ferring to INVO or its designee. In addition, Ferring shall provide INVO with a list of all then-existing
customers, of the Product in the Territory.
INVO’s
Supply Agreement with Ferring dated November 12, 2018 automatically terminates upon termination of the Agreement, pursuant to its terms.
As such, the Supply Agreement will terminate on January 31, 2022.
Item
8.01 Other Events
On
November 8, 2021, we issued a press release titled “INVO Bioscience Regains Full U.S. Commercialization Rights”. A copy of
the press release is filed hereto as Exhibit 99.1 and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
INVO
BIOSCIENCE, INC.
|
|
|
|
|
By:
|
/s/
Steven Shum
|
|
Name:
|
Steven
Shum
|
|
Title:
|
Chief
Executive Officer
|
|
|
|
Dated
November 8, 2021
|
|
|
INVO BioScience (NASDAQ:INVO)
Historical Stock Chart
From Feb 2024 to Mar 2024
INVO BioScience (NASDAQ:INVO)
Historical Stock Chart
From Mar 2023 to Mar 2024